The Relationship Between Medication Adherence on Blood Pressure and Quality of Life of Hipertensive Prolanis Participant at Demak Regency
Abstract
Optimal quality of life for people with hypertension is very important so as not to reduce patient productivity. Adherence drug use is one of the factors thought to be associated with blood pressure and quality of life. This study aims to determine the relationship between adherence to medication use on blood pressure and quality of life of patients with hypertension in Prolanis . participants at the First Level Health Facility of the Klinik Pratama.
This study used a cross sectional design involving hypertensive patients participating in Prolanis who met the inclusion and exclusion criteria at seven Primary Clinics in Demak Regency. Data on medication adherence were obtained using the MARS-5 questionnaire, quality of life data using the EQ-5D-5L questionnaire, and blood pressure data using a digital sphygmomanometer. The relationship between the level of compliance with blood pressure and the relationship between the level of compliance with quality of life was tested using Spearman rho analysis.
The results of the study with a total of 87 respondents showed that most of them had moderate levels of adherence (52%), systolic blood pressure (64%) and diastolic blood pressure (57%) were not controlled and the average utility score was 0.845. There is a relationship between drug use adherence to systolic and diastolic blood pressure (P = 0.009), (P = 0.032) with a weak correlation level (r = 0.27), (r = 0.23) and there is a relationship between drug use adherence on quality of life (P = 0.000) with a moderate level of correlation (r = 0.42).
References
[2] M. Wang et al., “Association between blood pressure levels and cardiovascular deaths: A 20-year follow-up study in rural China,” BMJ Open, vol. 10, no. 2, pp. 1–6, 2020, doi: 10.1136/bmjopen-2019-035190.
[3] BPJS, “Panduan praktis Prolanis (Program pengelolaan penyakit kronis),” BPJS Kesehat., 2014.
[4] A. S. Wahyuni and I. R. Lubis, “Kualitas Hidup Pasien Hipertensi Tanpa Komplikasi di Daerah Puskesmas Medan Labuhan,” Talent. Conf. Ser. Trop. Med., vol. 1, no. 2, pp. 374–380, 2018, doi: 10.32734/tm.v1i2.219.
[5] B. Artiyaningrum, “Faktor-Faktor Yang Berhubungan Dengan Kejadian Hipertensi Tidak Terkendali Pada Penderita Yang Melakukan Pemeriksaan Rutin di Puskesmas Kedungmundu Kota Semarang Tahun 2016,” Public Heal. Perspect. J., vol. 1, no. 1, pp. 12–20, 2016.
[6] S. Wicaksono and N. N. Fajriyah, “Hubungan Keaktifan dalam Klub Prolanis Terhadap Peningkatan Kualitas Hidup Diabetes Tipe 2,” J. Ilm. Kesehat., vol. XI, no. I, 2018.
[7] Dinas Kesehatan Provinsi Jawa Tengah, “Profil kesehatan Profinsi Jawa Tengah Tahun 2017,” vol. 3511351, no. 24, pp. 1–112, 2017.
[8] A. Firdiawan, T. M. Andayani, and S. A. Kristina, “Hubungan Kepatuhan Pengobatan Terhadap Outcome Klinik Pasien Diabetes Melitus Tipe 2 dengan Medication Adherence Rating Scale-5 (MARS-5),” Maj. Farm., vol. 17, no. 1, p. 22, 2021, doi: 10.22146/farmaseutik.v17i1.48053.
[9] G. C. Y. Kang, E. Y. L. Koh, and N. C. Tan, “Prevalence and factors associated with adherence to anti-hypertensives among adults with hypertension in a developed Asian community: A cross-sectional study,” Proc. Singapore Healthc., vol. 29, no. 3, pp. 167–175, 2020, doi: 10.1177/2010105820933305.
[10] N. Woodham, S. Taneepanichskul, R. Somrongthong, and N. Auamkul, “Medication adherence and associated factors among elderly hypertension patients with uncontrolled blood pressure in rural area, Northeast Thailand,” J. Heal. Res., vol. 32, no. 6, pp. 449–458, 2018, doi: 10.1108/JHR-11-2018-085.
[11] M. Dewi, I. P. Sari, and Probosuseno, “The Influence of the Pharmacists Counseling on Patient Adherence and Hypertension Control on Patient of Prolanis at Mitra Husada Clinics,” Indones. J. Clin. Pharm., vol. 4, no. 4, pp. 242–249, 2015, doi: 10.15416/ijcp.2015.4.4.242.
[12] N. Larasati and N. Husna, “PENGARUH PROLANIS DAN KEPATUHAN MINUM OBAT TERHADAP TEKANAN DARAH PASIEN HIPERTENSI DI PUSKESMAS GAMPING 1,” MEDIA ILMU Kesehat., vol. 8, no. 2, pp. 87–93, 2020, doi: 10.30989/mik.v8i2.293.
[13] Yusransyah, E. Halimah, and A. A. Suwantika, “Measurement of the quality of life of prolanis hypertension patients in sixteen primary healthcare centers in Pandeglang District, Banten Province, Indonesia, using EQ-5D-5L instrument,” Dove Press Patient Prefer. Adherence, vol. 14, pp. 1103–1109, 2020, doi: 10.2147/PPA.S249085.
[14] N. Hamida, M. Ulfa, R. N. H. Haris, D. Endarti, and C. Wiedyaningsih, “Pengukuran Kualitas Hidup Pasien Program Pengelolaan Penyakit Kronis (Prolanis) di Puskesmas Menggunakan Instrumen EQ-5D-5L,” Maj. Farm., vol. 15, no. 2, p. 67, 2019, doi: 10.22146/farmaseutik.v15i2.46328.
[15] F. Effendi, E. Tiahesara, and D. R. Azana, “Hubungan Tingkat Kepatuhan Minum Obat Dengan Tekanan Darah Pada Pasien Hipertensi Di Kelompok Pengelolaan Penyakit Kronis (Prolanis) Klinik Qita,” J. Farmamedika (Pharmamedica Journal), vol. 3, no. 2, pp. 90–100, 2018, doi: 10.47219/ath.v3i2.50.
[16] K. Anwar and R. Masnina, “Hubungan Kepatuhan Minum Obat Antihipertensi denganTekanan Darah Pada Lansia Penderita Hipertensi di Wilayah Kerja Puskesmas Air Putih Samarinda,” Borneo Student Res., vol. 1, no. 1, pp. 494–501, 2019, [Online]. Available: https://journals.umkt.ac.id/index.php/bsr/article/view/939.
[17] I. A. Liberty, P. Pariyana, E. Roflin, and L. Waris, “Determinan Kepatuhan Berobat Pasien Hipertensi Pada Fasilitas Kesehatan Tingkat I,” J. Penelit. dan Pengemb. Pelayanan Kesehat., vol. 1, no. 1, pp. 58–65, 2018, doi: 10.22435/jpppk.v1i1.428.
[18] L. N. Ozumba and G. U. Ndukwu, “The association between medication adherence and blood pressure control among hypertensive patients attending a tertiary hospital in south-south Nigeria,” Int. J. Res. Med. Sci., vol. 9, no. 4, p. 965, 2021, doi: 10.18203/2320-6012.ijrms20211338.
[19] Y. T. Li et al., “Medication Adherence and Blood Pressure Control Among Hypertensive Patients With Coexisting Long-Term Conditions in Primary Care Settings,” Med. (United States), vol. 95, no. 20, 2016, doi: 10.1097/MD.0000000000003572.
[20] H. Fares, J. J. DiNicolantonio, J. H. O’Keefe, and C. J. Lavie, “Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes,” Open Hear. BMJ J., vol. 3, no. 2, pp. 1–7, 2016, doi: 10.1136/openhrt-2016-000473.
[21] A. C. C. de Souza, J. W. P. Borges, and T. M. M. Moreira, “Quality of life and treatment adherence in hypertensive patients: Systematic review with meta-analysis,” Revista de Saude Publica, vol. 50. pp. 1–14, 2016, doi: 10.1590/S1518-8787.2016050006415.
[22] N. Afiani, D. Sargowo, and I. S. Rini, “Hubungan Kepatuhan Terapi terhadap Kualitas Hidup Pasien dengan Hipertensi Derajat II,” Dk, vol. 2, no. Oktober, pp. 2–10, 2014.
[23] V. Nurmalita, E. Annisaa, D. Pramono, E. S. Sunarsih, P. Kedungmundu, and K. Hidup, “Hubungan Kepatuhan Minum Obat Antihipertensi Terhadap Kualitas Hidup Pada Pasien Hipertensi,” Diponegoro Med. J. (Jurnal Kedokt. Diponegoro), vol. 8, no. 4, pp. 1366–1374, 2019.
[24] R. Chalik, T. Ahmad, and H. Hidayati, “Kepatuhan Pengobatan Dan Kualitas Hidup Pada Pasien Hipertensi Rawat Jalan Di Rumah Sakit X Kota Makassar,” Media Farm., vol. 17, no. 1, p. 85, 2021, doi: 10.32382/mf.v17i1.1983.
